Audit Review Table
Blue Cross and Blue Shield of New Mexico (Org ID: 1825, Sub ID: 9522, Medicaid, Spec Area: None, Spec Proj: None, Contract Number: None)

Measurement Year - 2021; Date & Timestamp - 6/9/2022 4:55:49 PM

This submission is on the stage: Submission Finalized						
Measure/Data Element	Benefit Offered	Rate	Status	Audit Designation	Comment	
Effectiveness of Care						
Weight Assessment and Counseling for Nutrition and Physical						
Activity for Children/Adolescents (WCC) Weight Assessment and Counseling for Nutrition and Physical						
Activity for Children/Adolescents - BMI percentile (Total)		66.67%	R	R	Reported	
Weight Assessment and Counseling for Nutrition and Physical						
Activity for Children/Adolescents - Counseling for Nutrition (Total)		57.42%	R	R	Reported	
Weight Assessment and Counseling for Nutrition and Physical Activity for Children/Adolescents - Counseling for Physical Activity		55.72%	R	R	Reported	
(Total)		55.1275	•••	.,	, noponiou	
Childhood Immunization Status (CIS)						
Childhood Immunization Status - DTaP		75.91%	R	R	Reported	
Childhood Immunization Status - IPV		89.05%	R	R	Reported	
Childhood Immunization Status - MMR		86.13%	R	R	Reported	
Childhood Immunization Status - HiB		87.35%	R	R	Reported	
Childhood Immunization Status - Hepatitis B		89.05%	R	R	Reported	
Childhood Immunization Status - VZV		86.37%	R	R	Reported	
Childhood Immunization Status - Pneumococcal Conjugate		75.67%	R	R	Reported	
Childhood Immunization Status - Hepatitis A		86.62%	R	R	Reported	
Childhood Immunization Status - Rotavirus		75.18%	R	R	Reported	
Childhood Immunization Status - Influenza		52.07%	R	R	Reported	
Childhood Immunization Status - Combo 3		69.59%	R	R	Reported	
Childhood Immunization Status - Combo 7		61.31%	R	R	Reported	
Childhood Immunization Status - Combo 10		41.12%	R	R	Reported	
Immunizations for Adolescents (IMA)		41.1270	11	1	Reported	
Immunizations for Adolescents - Meningococcal		79.32%	R	R	Reported	
Immunizations for Adolescents - Trap		80.05%	R	R	Reported	
Immunizations for Adolescents - HPV		30.9%	R	R		
Immunizations for Adolescents - Combination 1			R	R	Reported	
		78.35% 30.17%	R	R	Reported	
Immunizations for Adolescents - Combination 2		30.17%	ĸ	R	Reported	
Lead Screening in Children (LSC)		40.070/	D	2	Denominal	
Lead Screening in Children		40.97%	R	R	Reported	
Breast Cancer Screening (BCS)		40.000/			5	
Breast Cancer Screening		40.98%	R	R	Reported	
Cervical Cancer Screening (CCS)			_	_		
Cervical Cancer Screening		50.12%	R	R	Reported	
Chlamydia Screening in Women (CHL)			_	-	_	
Chlamydia Screening in Women (Total)		48.16%	R	R	Reported	
Appropriate Testing for Pharyngitis (CWP)	Y					
Appropriate Testing for Pharyngitis (Total)		66.24%	R	R	Reported	
Use of Spirometry Testing in the Assessment and Diagnosis of COPD (SPR)						
Use of Spirometry Testing in the Assessment and Diagnosis of			_	_		
COPD		23.11%	R	R	Reported	
Pharmacotherapy Management of COPD Exacerbation (PCE)	Y					
Pharmacotherapy Management of COPD Exacerbation - Systemic		42.12%	R	R	Reported	
Corticosteroid		42.1270	K	K	Reported	
Pharmacotherapy Management of COPD Exacerbation - Bronchodilator		49.88%	R	R	Reported	
Asthma Medication Ratio (AMR)	Y					
Asthma Medication Ratio (AMR) Asthma Medication Ratio (Total)	'	75.28%	R	R	Reported	
Controlling High Blood Pressure (CBP)		75.26%	K	K	Reported	
` /		4C 470/	R	R	Reported	
Controlling High Blood Pressure Persistence of Beta-Blocker Treatment After a Heart Attack		46.47%	R	R	Reported	
(PBH)	Υ					
Persistence of Beta-Blocker Treatment After a Heart Attack		64.47%	R	R	Reported	
Statin Therapy for Patients With Cardiovascular Disease (SPC)	Υ					
. , ,	ľ					
Statin Therapy for Patients With Cardiovascular Disease - Received		61.69%	R	R	Reported	
Statin Therapy (Total) Statin Therapy for Patients With Cardiovascular Disease - Statin						
Adherence 80% (Total)		61.97%	R	R	Reported	
Cardiac Rehabilitation (CRE)						
Cardiac Rehabilitation - Initiation (Total)		3.71%	R	R	Reported	
Cardiac Rehabilitation - Engagement1 (Total)		4.35%	R	R	Reported	
Cardiac Rehabilitation - Engagement2 (Total)		2.9%	R	R	Reported	
Cardiac Rehabilitation - Achievement (Total)		2.26%	R	R	Reported	
Comprehensive Diabetes Care (CDC)					,,	
Comprehensive Diabetes Care - HbA1c Testing		80.05%	R	R	Reported	
Comprehensive Diabetes Care - Poor HbA1c Control		51.34%	R	R	Reported	
Comprehensive Diabetes Care - Poor FIDA IC COntrol		31.34%		I K	керопеа	

				т	
Comprehensive Diabetes Care - HbA1c Control (<8%)		42.82%	R	R	Reported
Comprehensive Diabetes Care - Eye Exams		42.34%	R	R	Reported
Comprehensive Diabetes Care - Blood Pressure Control (<140/90)		48.66%	R	R	Reported
Kidney Health Evaluation for Patients With Diabetes (KED)					
Kidney Health Evaluation for Patients With Diabetes (Total)		29.73%	R	R	Reported
Statin Therapy for Patients With Diabetes (SPD)	Y				
Statin Therapy for Patients With Diabetes - Received Statin Therapy		47.73%	R	R	Reported
Statin Therapy for Patients With Diabetes - Statin Adherence 80%		59.71%	R	R	Reported
Antidepressant Medication Management (AMM)	Y				
Antidepressant Medication Management - Effective Acute Phase Treatment		59.41%	R	R	Reported
Antidepressant Medication Management - Effective Continuation Phase Treatment		40.63%	R	R	Reported
Follow-Up Care for Children Prescribed ADHD Medication (ADD)	Y				
Follow-Up Care for Children Prescribed ADHD Medication - Initiation Phase		39.78%	R	R	Reported
Follow-Up Care for Children Prescribed ADHD Medication - Continuation and Maintenance Phase		55.06%	R	R	Reported
Follow-up After Hospitalization for Mental Illness (FUH)	Y				
Follow-Up After Hospitalization For Mental Illness - 30 days (Total)		56.6%	R	R	Reported
Follow-Up After Hospitalization For Mental Illness - 7 days (Total)		36.4%	R	R	Reported
Follow-Up After Emergency Department Visit for Mental Illness	Y				
(FUM) Follow-Up After Emergency Department Visit for Mental Illness - 30	'		_	_	_
days (Total) Follow-Up After Emergency Department Visit for Mental Illness - 7		56.57%	R	R	Reported
days (Total)		42.83%	R	R	Reported
Follow-Up After High-Intensity Care for Substance Use Disorder (FUI)	Υ				
Follow-Up After High-Intensity Care for Substance Use Disorder - 30 days (Total)		44.42%	R	R	Reported
Follow-Up After High-Intensity Care for Substance Use Disorder - 7 Days (Total)		21.44%	R	R	Reported
Follow-Up After Emergency Department Visit for Alcohol and	Y				
Other Drug Abuse or Dependence (FUA) Follow-Up After Emergency Department Visit for Alcohol and Other		23.67%	R	R	Reported
Drug Abuse or Dependence - 30 days (Total) Follow-Up After Emergency Department Visit for Alcohol and Other		15.86%	R	R	Reported
Drug Abuse or Dependence - 7 days (Total) Pharmacotherapy for Opioid Use Disorder (POD)	Y	13.00 %	K	IX.	Reported
Pharmacotherapy for Opioid Use Disorder (Total)	'	17.32%	R	R	Reported
Diabetes Screening for People With Schizophrenia or Bipolar	.,	17.0270	N.	IX.	rtoported
Disorder Who Are Using Antipsychotic Medications (SSD)	Y				
Diabetes Screening for People With Schizophrenia or Bipolar Disorder Who Are Using Antipsychotic Medications		77.59%	R	R	Reported
Diabetes Monitoring for People With Diabetes and					
Schizophrenia (SMD)					
Diabetes Monitoring for People With Diabetes and Schizophrenia			NR	NR	Not Reported
Cardiovascular Monitoring for People With Cardiovascular					
Disease and Schizophrenia (SMC) Cardiovascular Monitoring for People With Cardiovascular Disease			ND	ND	Not
and Schizophrenia			NR	NR	Reported
Adherence to Antipsychotic Medications for Individuals With Schizophrenia (SAA)	Y				
Adherence to Antipsychotic Medications for Individuals With Schizophrenia		51.6%	R	R	Reported
Metabolic Monitoring for Children and Adolescents on	Y				
Antipsychotics (APM) Metabolic Monitoring for Children and Adolescents on Antipsychotics -		56.07%	R	R	Reported
Blood Glucose Testing (Total) Metabolic Monitoring for Children and Adolescents on Antipsychotics			R	R	<u> </u>
Cholesterol Testing (Total) Metabolic Monitoring for Children and Adolescents on Antipsychotics		28.79%			Reported
Blood Glucose and Cholesteris on Anipsycholoss - Blood Glucose and Cholesterol Testing (Total) Non-Recommended Cervical Cancer Screening in Adolescent		28.21%	R	R	Reported
Females (NCS)					
Non-Recommended Cervical Cancer Screening in Adolescent Females		0.42%	R	R	Reported
Appropriate Treatment for Upper Respiratory Infection (URI)	Υ				
Appropriate Treatment for Upper Respiratory Infection (Total)		83.38%	R	R	Reported
Avoidance of Antibiotic Treatment for Acute	Y				
Bronchitis/Bronchiolitis (AAB) Avoidance of Antibiotic Treatment for Acute Bronchitis/Bronchiolitis		10.0401	5		D
(Total)		48.64%	R	R	Reported
Use of Imaging Studies for Low Back Pain (LBP)					
		72.72%	R	R	Reported
Use of Imaging Studies for Low Back Pain Use of Opioids at High Dosage (HDO)	Υ				

Use of Opioids From Multiple Providers (UOP)	V				
Use of Opioids From Multiple Providers - Multiple Prescribers	Y	14.45%	R	R	Reported
Use of Opioids From Multiple Providers - Multiple Pharmacies		1.53%	R	R	Reported
Use of Opioids From Multiple Providers - Multiple Prescribers and		0.88%	R	R	Reported
Multiple Pharmacies	.,	0.86%	K	K	Reported
Risk of Continued Opioid Use (COU) Risk of Continued Opioid Use - >=15 Days (Total)	Y	4.98%	R	R	Deported
Risk of Continued Opioid Use - >=15 Days (Total) Risk of Continued Opioid Use - >=31 Days (Total)		3.58%	R	R	Reported Reported
Access/Availability of Care		0.0070	1,	11	rteported
Adults' Access to Preventive/Ambulatory Health Services (AAP)					
. , ,		74.000/	D	D	Denombed
Adults' Access to Preventive/Ambulatory Health Services (Total) Annual Dental Visit (ADV)	Y	74.22%	R	R	Reported
Annual Dental Visit (ADV) Annual Dental Visit (Total)	T	53.51%	R	R	Reported
Initiation and Engagement of Alcohol and Other Drug Abuse or	Y	00.0170	.,		riopolica
Dependence Treatment (IET)	'				
Initiation and Engagement of Alcohol and Other Drug Abuse or Dependence Treatment - Initiation of AOD - Alcohol Abuse or		42.27%	R	R	Reported
Dependence (Total)					
Initiation and Engagement of Alcohol and Other Drug Abuse or		12.759/	R	R	Danastad
Dependence Treatment - Engagement of AOD - Alcohol Abuse or Dependence (Total)		13.75%	ĸ	K	Reported
Initiation and Engagement of Alcohol and Other Drug Abuse or					
Dependence Treatment - Initiation of AOD - Opioid Abuse or Dependence (Total)		54.41%	R	R	Reported
Initiation and Engagement of Alcohol and Other Drug Abuse or					
Dependence Treatment - Engagement of AOD - Opioid Abuse or		19.57%	R	R	Reported
Dependence (Total)					
Initiation and Engagement of Alcohol and Other Drug Abuse or Dependence Treatment - Initiation of AOD - Other Drug Abuse or		41.59%	R	R	Reported
Dependence (Total)					Поролюс
Initiation and Engagement of Alcohol and Other Drug Abuse or		40.000			Demonstrat
Dependence Treatment - Engagement of AOD - Other Drug Abuse or Dependence (Total)		12.2%	R	R	Reported
Initiation and Engagement of Alcohol and Other Drug Abuse or		42.91%	R	R	Reported
Dependence Treatment - Initiation of AOD - Total (Total)		42.5170	K	IX.	Reported
Initiation and Engagement of Alcohol and Other Drug Abuse or Dependence Treatment - Engagement of AOD - Total (Total)		14.37%	R	R	Reported
Prenatal and Postpartum Care (PPC)					
Prenatal and Postpartum Care - Timeliness of Prenatal Care		82%	R	R	Reported
Prenatal and Postpartum Care - Postpartum Care		69.1%	R	R	Reported
Use of First-Line Psychosocial Care for Children and	Y				
Adolescents on Antipsychotics (APP)					
Use of First-Line Psychosocial Care for Children and Adolescents on		E7 140/	P	В	Papartad
Antipsychotics (Total)		57.14%	R	R	Reported
Antipsychotics (Total) Utilization		57.14%	R	R	Reported
Antipsychotics (Total) Utilization Well-Child Visits in the First 30 Months of Life (W30)					
Antipsychotics (Total) Utilization Well-Child Visits in the First 30 Months of Life (W30) Well-Child Visits in the First 30 Months of Life (First 15 Months)		58.54%	R	R	Reported
Antipsychotics (Total) Utilization Well-Child Visits in the First 30 Months of Life (W30)					
Antipsychotics (Total) Utilization Well-Child Visits in the First 30 Months of Life (W30) Well-Child Visits in the First 30 Months of Life (First 15 Months) Well-Child Visits in the First 30 Months of Life (15 Months-30 Months) Child and Adolescent Well-Care Visits (WCV)		58.54% 63.22%	R R	R R	Reported Reported
Antipsychotics (Total) Utilization Well-Child Visits in the First 30 Months of Life (W30) Well-Child Visits in the First 30 Months of Life (First 15 Months) Well-Child Visits in the First 30 Months of Life (15 Months-30 Months) Child and Adolescent Well-Care Visits (WCV) Child and Adolescent Well-Care Visits (Total)		58.54%	R R R	R R R	Reported Reported Reported
Antipsychotics (Total) Utilization Well-Child Visits in the First 30 Months of Life (W30) Well-Child Visits in the First 30 Months of Life (First 15 Months) Well-Child Visits in the First 30 Months of Life (15 Months-30 Months) Child and Adolescent Well-Care Visits (WCV) Child and Adolescent Well-Care Visits (Total) Frequency of Selected Procedures (FSP)		58.54% 63.22%	R R R R	R R R R	Reported Reported Reported Reported
Antipsychotics (Total) Utilization Well-Child Visits in the First 30 Months of Life (W30) Well-Child Visits in the First 30 Months of Life (First 15 Months) Well-Child Visits in the First 30 Months of Life (15 Months-30 Months) Child and Adolescent Well-Care Visits (WCV) Child and Adolescent Well-Care Visits (Total) Frequency of Selected Procedures (FSP) Ambulatory Care (AMBa)		58.54% 63.22%	R R R R	R R R R	Reported Reported Reported Reported Reported Reported
Antipsychotics (Total) Utilization Well-Child Visits in the First 30 Months of Life (W30) Well-Child Visits in the First 30 Months of Life (First 15 Months) Well-Child Visits in the First 30 Months of Life (15 Months-30 Months) Child and Adolescent Well-Care Visits (WCV) Child and Adolescent Well-Care Visits (Total) Frequency of Selected Procedures (FSP)		58.54% 63.22%	R R R R	R R R R	Reported Reported Reported Reported Reported Not Reported
Antipsychotics (Total) Utilization Well-Child Visits in the First 30 Months of Life (W30) Well-Child Visits in the First 30 Months of Life (First 15 Months) Well-Child Visits in the First 30 Months of Life (15 Months-30 Months) Child and Adolescent Well-Care Visits (WCV) Child and Adolescent Well-Care Visits (Total) Frequency of Selected Procedures (FSP) Ambulatory Care (AMBa)		58.54% 63.22%	R R R R	R R R R	Reported Reported Reported Reported Reported Reported Not Reported Not
Antipsychotics (Total) Utilization Well-Child Visits in the First 30 Months of Life (W30) Well-Child Visits in the First 30 Months of Life (First 15 Months) Well-Child Visits in the First 30 Months of Life (15 Months-30 Months) Child and Adolescent Well-Care Visits (WCV) Child and Adolescent Well-Care Visits (Total) Frequency of Selected Procedures (FSP) Ambulatory Care (AMBa) Ambulatory Care (Dual) (AMBb)		58.54% 63.22%	R R R R R NR	R R R R R R NR	Reported Reported Reported Reported Reported Not Reported
Antipsychotics (Total) Utilization Well-Child Visits in the First 30 Months of Life (W30) Well-Child Visits in the First 30 Months of Life (First 15 Months) Well-Child Visits in the First 30 Months of Life (15 Months-30 Months) Child and Adolescent Well-Care Visits (WCV) Child and Adolescent Well-Care Visits (Total) Frequency of Selected Procedures (FSP) Ambulatory Care (AMBa) Ambulatory Care (Dual) (AMBb) Ambulatory Care (Disabled) (AMBc) Ambulatory Care (Low Income) (AMBd)		58.54% 63.22%	R R R R R R R NR	R R R R R R NR NR	Reported Reported Reported Reported Reported Not Reported Not Reported Not Reported Not Reported Not Reported
Antipsychotics (Total) Utilization Well-Child Visits in the First 30 Months of Life (W30) Well-Child Visits in the First 30 Months of Life (First 15 Months) Well-Child Visits in the First 30 Months of Life (15 Months-30 Months) Child and Adolescent Well-Care Visits (WCV) Child and Adolescent Well-Care Visits (Total) Frequency of Selected Procedures (FSP) Ambulatory Care (AMBa) Ambulatory Care (Dual) (AMBb)		58.54% 63.22%	R R R R R NR	R R R R R R NR	Reported Reported Reported Reported Reported Not Reported Not Reported Not Reported Reported Reported Reported
Antipsychotics (Total) Utilization Well-Child Visits in the First 30 Months of Life (W30) Well-Child Visits in the First 30 Months of Life (First 15 Months) Well-Child Visits in the First 30 Months of Life (15 Months-30 Months) Child and Adolescent Well-Care Visits (WCV) Child and Adolescent Well-Care Visits (Total) Frequency of Selected Procedures (FSP) Ambulatory Care (AMBa) Ambulatory Care (Dual) (AMBb) Ambulatory Care (Disabled) (AMBc) Ambulatory Care (Low Income) (AMBd)		58.54% 63.22%	R R R R R R R NR	R R R R R R NR NR	Reported Reported Reported Reported Reported Not Reported Not Reported Not Reported Not Reported Not Reported
Antipsychotics (Total) Utilization Well-Child Visits in the First 30 Months of Life (W30) Well-Child Visits in the First 30 Months of Life (First 15 Months) Well-Child Visits in the First 30 Months of Life (First 15 Months-30 Months) Child and Adolescent Well-Care Visits (WCV) Child and Adolescent Well-Care Visits (Total) Frequency of Selected Procedures (FSP) Ambulatory Care (AMBa) Ambulatory Care (Dual) (AMBb) Ambulatory Care (Disabled) (AMBc) Ambulatory Care (Low Income) (AMBd) Inpatient Utilization - General Hospital/Acute Care (Dual) (IPUb) Inpatient Utilization - General Hospital/Acute Care (Disabled)		58.54% 63.22%	R R R R R R NR NR NR NR	R R R R R R NR NR NR	Reported Reported Reported Reported Not Reported
Antipsychotics (Total) Utilization Well-Child Visits in the First 30 Months of Life (W30) Well-Child Visits in the First 30 Months of Life (First 15 Months) Well-Child Visits in the First 30 Months of Life (15 Months-30 Months) Child and Adolescent Well-Care Visits (WCV) Child and Adolescent Well-Care Visits (Total) Frequency of Selected Procedures (FSP) Ambulatory Care (AMBa) Ambulatory Care (Dual) (AMBb) Ambulatory Care (Disabled) (AMBc) Ambulatory Care (Low Income) (AMBd) Inpatient Utilization - General Hospital/Acute Care (IPUa) Inpatient Utilization - General Hospital/Acute Care (Disabled) (IPUb)		58.54% 63.22%	R R R R R R NR NR NR NR NR	R R R R R R NR NR NR NR	Reported Reported Reported Reported Reported Not Reported Not Reported Not Reported Not Reported Reported Not Reported Reported Reported Not Reported Reported Not Reported Reported Not Reported Reported
Antipsychotics (Total) Utilization Well-Child Visits in the First 30 Months of Life (W30) Well-Child Visits in the First 30 Months of Life (First 15 Months) Well-Child Visits in the First 30 Months of Life (First 15 Months-30 Months) Child and Adolescent Well-Care Visits (WCV) Child and Adolescent Well-Care Visits (Total) Frequency of Selected Procedures (FSP) Ambulatory Care (AMBa) Ambulatory Care (Dual) (AMBb) Ambulatory Care (Disabled) (AMBc) Ambulatory Care (Low Income) (AMBd) Inpatient Utilization - General Hospital/Acute Care (Dual) (IPUb) Inpatient Utilization - General Hospital/Acute Care (Disabled)		58.54% 63.22%	R R R R R R NR NR NR NR	R R R R R R NR NR NR	Reported Reported Reported Reported Not
Antipsychotics (Total) Utilization Well-Child Visits in the First 30 Months of Life (W30) Well-Child Visits in the First 30 Months of Life (First 15 Months) Well-Child Visits in the First 30 Months of Life (First 15 Months) Well-Child Visits in the First 30 Months of Life (15 Months) Child and Adolescent Well-Care Visits (WCV) Child and Adolescent Well-Care Visits (Total) Frequency of Selected Procedures (FSP) Ambulatory Care (AMBa) Ambulatory Care (Dual) (AMBb) Ambulatory Care (Disabled) (AMBc) Ambulatory Care (Low Income) (AMBd) Inpatient Utilization - General Hospital/Acute Care (IPUa) Inpatient Utilization - General Hospital/Acute Care (Disabled) (IPUc) Inpatient Utilization - General Hospital/Acute Care (Low Income)		58.54% 63.22%	R R R R R R NR NR NR NR NR	R R R R R R NR NR NR NR	Reported Reported Reported Reported Reported Not Reported Not Reported Not Reported Not Reported Not Reported Not Reported Reported Reported Reported Not Reported Reported Reported Reported Reported Reported Reported Reported Reported
Antipsychotics (Total) Utilization Well-Child Visits in the First 30 Months of Life (W30) Well-Child Visits in the First 30 Months of Life (First 15 Months) Well-Child Visits in the First 30 Months of Life (First 15 Months) Well-Child Visits in the First 30 Months of Life (15 Months) Child and Adolescent Well-Care Visits (WCV) Child and Adolescent Well-Care Visits (Total) Frequency of Selected Procedures (FSP) Ambulatory Care (AMBa) Ambulatory Care (Dual) (AMBb) Ambulatory Care (Disabled) (AMBc) Ambulatory Care (Low Income) (AMBd) Inpatient Utilization - General Hospital/Acute Care (IPUa) Inpatient Utilization - General Hospital/Acute Care (Disabled) (IPUb) Inpatient Utilization - General Hospital/Acute Care (Low Income) (IPUd)		58.54% 63.22%	R R R R R R R NR NR NR NR NR	R R R R R R NR NR NR NR NR	Reported Reported Reported Reported Not Reported Not Reported Not Reported Not Reported Not Reported Not Reported Reported Reported Not Reported Reported
Antipsychotics (Total) Utilization Well-Child Visits in the First 30 Months of Life (W30) Well-Child Visits in the First 30 Months of Life (First 15 Months) Well-Child Visits in the First 30 Months of Life (First 15 Months-30 Months) Child and Adolescent Well-Care Visits (WCV) Child and Adolescent Well-Care Visits (Total) Frequency of Selected Procedures (FSP) Ambulatory Care (AMBa) Ambulatory Care (Dual) (AMBb) Ambulatory Care (Disabled) (AMBc) Ambulatory Care (Disabled) (AMBc) Inpatient Utilization - General Hospital/Acute Care (IPUa) Inpatient Utilization - General Hospital/Acute Care (Disabled) (IPUc) Inpatient Utilization - General Hospital/Acute Care (Low Income) (IPUd) Inpatient Utilization - General Hospital/Acute Care (Low Income) (IPUd) Identification of Alcohol and other Drug Services (IADa)		58.54% 63.22%	R R R R R R R NR NR NR NR NR NR NR NR NR	R R R R R R NR NR NR NR NR NR R NR NR NR	Reported Reported Reported Reported Reported Not Reported Not Reported Not Reported Not Reported Not Reported Not Reported Reported Reported Reported Not Reported Reported Reported Reported Reported Reported Reported Reported Reported
Antipsychotics (Total) Utilization Well-Child Visits in the First 30 Months of Life (W30) Well-Child Visits in the First 30 Months of Life (First 15 Months) Well-Child Visits in the First 30 Months of Life (15 Months-30 Months) Child and Adolescent Well-Care Visits (WCV) Child and Adolescent Well-Care Visits (Total) Frequency of Selected Procedures (FSP) Ambulatory Care (AMBa) Ambulatory Care (Dual) (AMBb) Ambulatory Care (Disabled) (AMBc) Ambulatory Care (Low Income) (AMBd) Inpatient Utilization - General Hospital/Acute Care (IPUa) Inpatient Utilization - General Hospital/Acute Care (Dual) (IPUb) Inpatient Utilization - General Hospital/Acute Care (Low Income) (IPUc) Inpatient Utilization - General Hospital/Acute Care (Low Income) (IPUd) Identification of Alcohol and Other Drug Services (Dual) (IADb) Identification of Alcohol and Other Drug Services (Disabled) (IADb)		58.54% 63.22%	R R R R R R NR NR NR NR NR NR NR NR NR	R R R R R R NR NR NR NR NR NR NR NR NR N	Reported Reported Reported Reported Reported Not Reported Reported Reported Reported Reported Reported Reported Reported Reported Not Reported Not Reported
Mell-Child Visits in the First 30 Months of Life (W30) Well-Child Visits in the First 30 Months of Life (First 15 Months) Well-Child Visits in the First 30 Months of Life (First 15 Months) Well-Child Visits in the First 30 Months of Life (15 Months-30 Months) Child and Adolescent Well-Care Visits (WCV) Child and Adolescent Well-Care Visits (Total) Frequency of Selected Procedures (FSP) Ambulatory Care (AMBa) Ambulatory Care (Dual) (AMBb) Ambulatory Care (Disabled) (AMBc) Ambulatory Care (Disabled) (AMBc) Inpatient Utilization - General Hospital/Acute Care (IPUa) Inpatient Utilization - General Hospital/Acute Care (Dual) (IPUb) Inpatient Utilization - General Hospital/Acute Care (Low Income) (IPUc) Inpatient Utilization - General Hospital/Acute Care (Low Income) (IPUd) Identification of Alcohol and other Drug Services (IADa) Identification of Alcohol and Other Drug Services (Disabled) (IADb) Identification of Alcohol and Other Drug Services (Low Income)		58.54% 63.22%	R R R R R R R NR NR NR NR NR NR NR NR NR	R R R R R R NR NR NR NR NR NR R NR NR NR	Reported Reported Reported Reported Reported Not
Antipsychotics (Total) Well-Child Visits in the First 30 Months of Life (W30) Well-Child Visits in the First 30 Months of Life (First 15 Months) Well-Child Visits in the First 30 Months of Life (15 Months-30 Months) Child and Adolescent Well-Care Visits (WCV) Child and Adolescent Well-Care Visits (Total) Frequency of Selected Procedures (FSP) Ambulatory Care (AMBa) Ambulatory Care (Dual) (AMBb) Ambulatory Care (Disabled) (AMBc) Ambulatory Care (Low Income) (AMBd) Inpatient Utilization - General Hospital/Acute Care (IPUa) Inpatient Utilization - General Hospital/Acute Care (Disabled) (IPUc) Inpatient Utilization - General Hospital/Acute Care (Low Income) (IPUd) Identification of Alcohol and Other Drug Services (Dual) (IADb) Identification of Alcohol and Other Drug Services (Disabled) (IADb)		58.54% 63.22%	R R R R R R NR NR NR NR NR NR NR NR NR N	R R R R R R NR NR NR NR NR NR NR NR NR N	Reported Reported Reported Reported Reported Not Reported Not Reported Not Reported Not Reported Not Reported Reported Not Reported Reported Reported Reported Reported Not Reported Not Reported Not Reported
Mell-Child Visits in the First 30 Months of Life (W30) Well-Child Visits in the First 30 Months of Life (First 15 Months) Well-Child Visits in the First 30 Months of Life (First 15 Months) Well-Child Visits in the First 30 Months of Life (15 Months-30 Months) Child and Adolescent Well-Care Visits (WCV) Child and Adolescent Well-Care Visits (Total) Frequency of Selected Procedures (FSP) Ambulatory Care (AMBa) Ambulatory Care (Dual) (AMBb) Ambulatory Care (Disabled) (AMBc) Ambulatory Care (Disabled) (AMBc) Inpatient Utilization - General Hospital/Acute Care (IPUa) Inpatient Utilization - General Hospital/Acute Care (Dual) (IPUb) Inpatient Utilization - General Hospital/Acute Care (Low Income) (IPUc) Inpatient Utilization - General Hospital/Acute Care (Low Income) (IPUd) Identification of Alcohol and other Drug Services (IADa) Identification of Alcohol and Other Drug Services (Disabled) (IADb) Identification of Alcohol and Other Drug Services (Low Income) (IADd) Mental Health Utilization (MPTa)	Y	58.54% 63.22%	R R R R R R R NR NR NR NR NR NR NR NR NR	R R R R R R NR NR NR NR NR NR NR NR NR N	Reported Reported Reported Reported Reported Not Reported Reported Reported Reported Reported Not Reported Reported Not
Utilization Well-Child Visits in the First 30 Months of Life (W30) Well-Child Visits in the First 30 Months of Life (First 15 Months) Well-Child Visits in the First 30 Months of Life (First 15 Months) Well-Child Visits in the First 30 Months of Life (15 Months) Child and Adolescent Well-Care Visits (WCV) Child and Adolescent Well-Care Visits (Total) Frequency of Selected Procedures (FSP) Ambulatory Care (AMBa) Ambulatory Care (Dual) (AMBb) Ambulatory Care (Disabled) (AMBc) Inpatient Utilization - General Hospital/Acute Care (IPUa) Inpatient Utilization - General Hospital/Acute Care (Disabled) (IPUb) Inpatient Utilization - General Hospital/Acute Care (Low Income) (IPUd) Identification of Alcohol and other Drug Services (IADa) Identification of Alcohol and Other Drug Services (Disabled) (IADb) Identification of Alcohol and Other Drug Services (Low Income) (IADd) Mental Health Utilization (MPTa) Mental Health Utilization (Dual) (MPTb)	Y	58.54% 63.22%	R R R R R R R NR NR NR NR NR NR NR NR NR	R R R R R R R NR NR NR NR NR NR NR NR NR	Reported Reported Reported Reported Reported Not Reported Reported Reported Not Reported Reported Not Reported Reported Reported
Utilization Well-Child Visits in the First 30 Months of Life (W30) Well-Child Visits in the First 30 Months of Life (First 15 Months) Well-Child Visits in the First 30 Months of Life (First 15 Months-30 Months) Child and Adolescent Well-Care Visits (WCV) Child and Adolescent Well-Care Visits (Total) Frequency of Selected Procedures (FSP) Ambulatory Care (AMBa) Ambulatory Care (Dual) (AMBb) Ambulatory Care (Disabled) (AMBc) Ambulatory Care (Disabled) (AMBc) Inpatient Utilization - General Hospital/Acute Care (IPUa) Inpatient Utilization - General Hospital/Acute Care (Dual) (IPUb) Inpatient Utilization - General Hospital/Acute Care (Low Income) (IPUc) Inpatient Utilization - General Hospital/Acute Care (Low Income) (IPUd) Identification of Alcohol and other Drug Services (IADa) Identification of Alcohol and Other Drug Services (Disabled) (IADb) Identification of Alcohol and Other Drug Services (Low Income) (IADd) Mental Health Utilization (MPTa)	Y	58.54% 63.22%	R R R R R R R NR NR NR NR NR NR NR NR NR	R R R R R R NR NR NR NR NR NR NR NR NR N	Reported Reported Reported Reported Reported Not Reported Reported Reported Reported Reported Not Reported Reported
Utilization Well-Child Visits in the First 30 Months of Life (W30) Well-Child Visits in the First 30 Months of Life (First 15 Months) Well-Child Visits in the First 30 Months of Life (First 15 Months) Well-Child Visits in the First 30 Months of Life (15 Months) Child and Adolescent Well-Care Visits (WCV) Child and Adolescent Well-Care Visits (Total) Frequency of Selected Procedures (FSP) Ambulatory Care (AMBa) Ambulatory Care (Dual) (AMBb) Ambulatory Care (Disabled) (AMBc) Inpatient Utilization - General Hospital/Acute Care (IPUa) Inpatient Utilization - General Hospital/Acute Care (Disabled) (IPUb) Inpatient Utilization - General Hospital/Acute Care (Low Income) (IPUd) Identification of Alcohol and other Drug Services (IADa) Identification of Alcohol and Other Drug Services (Disabled) (IADb) Identification of Alcohol and Other Drug Services (Low Income) (IADd) Mental Health Utilization (MPTa) Mental Health Utilization (Dual) (MPTb)	Y	58.54% 63.22%	R R R R R R R NR NR NR NR NR NR NR NR NR	R R R R R R R NR NR NR NR NR NR NR NR NR	Reported Reported Reported Reported Reported Reported Not Reported Reported Reported Not

Antibiotic Utilization (Dual) (ABXb)	NR	NR	Not Reported
Antibiotic Utilization (Disabled) (ABXc)	NR	NR	Not Reported
Antibiotic Utilization (Low Income) (ABXd)	NR	NR	Not Reported
Risk Adjusted Utilization			reported
Plan All-Cause Readmissions (PCR)	R	R	Reported
Health Plan Descriptive Information			
Enrollment by Product Line (ENPa)	R	R	Reported
Enrollment by Product Line (Dual) (ENPb)	NR	NR	Not Reported
Enrollment by Product Line (Disabled) (ENPc)	NR	NR	Not Reported
Enrollment by Product Line (Low Income) (ENPd)	NR	NR	Not Reported
Language Diversity of Membership (LDM)	NR	NR	Not Reported
Race/Ethnicity Diversity of Membership (RDM)	NR	NR	Not Reported
Electronic Clinical Data Systems	 		
Breast Cancer Screening (BCS-E)			
Breast Cancer Screening	NR	NR	Not Reported
Follow-Up Care for Children Prescribed ADHD Medication (ADD-			reported
Follow-Up Care for Children Prescribed ADHD Medication - Initiation Phase	NR	NR	Not Reported
Follow-Up Care for Children Prescribed ADHD Medication - Continuation and Maintenance Phase	NR	NR	Not Reported
Depression Screening and Follow-Up for Adolescents and Adults (DSF-E)			Поролов
Depression Screening and Follow-Up for Adolescents and Adults - Depression Screening (Total)	NR	NR	Not Reported
Depression Screening and Follow-Up for Adolescents and Adults - Follow-up on Positive Screen (Total)	NR	NR	Not Reported
Utilization of the PHQ-9 to Monitor Depression Symptoms for			Reported
Adolescents and Adults (DMS-E) Utilization of the PHQ-9 to Monitor Depression Symptoms for Adolescents and Adults - Utilization of PHQ-9-Period1 (Total)	NR	NR	Not Reported
Utilization of the PHQ-9 to Monitor Depression Symptoms for Adolescents and Adults - Utilization of PHQ-9-Period2 (Total)	NR	NR	Not Reported
Utilization of the PHQ-9 to Monitor Depression Symptoms for Adolescents and Adults - Utilization of PHQ-9-Period3 (Total)	NR	NR	Not Reported
Utilization of the PHQ-9 to Monitor Depression Symptoms for Adolescents and Adults - Utilization of PHQ-9-Total (Total)	NR	NR	Not Reported
Depression Remission or Response for Adolescents and Adults			reported
(DRR-E) Depression Remission or Response for Adolescents and Adults -	NR	NR	Not
Follow-up PHQ-9 (Total) Depression Remission or Response for Adolescents and Adults -	NR	NR	Reported
Depression Remission (Total) Depression Remission or Response for Adolescents and Adults -	NR	NR	Reported Not
Depression Response (Total)			Reported
Unhealthy Alcohol Use Screening and Follow-Up (ASF-E) Unhealthy Alcohol Use Screening and Follow-Up - Unhealthy Alcohol			Net
Use Screening (Total)	NR	NR	Not Reported
Unhealthy Alcohol Use Screening and Follow-Up - Alcohol	NR	NR	Not
Counseling or Other Follow-Up Care (Total)	INIX	INIX	Reported
Adult Immunization Status (AIS-E)			Not
Adult Immunization Status - Influenza	NR	NR	Reported
Adult Immunization Status - Td/Tdap	NR	NR	Reported Not
Adult Immunization Status (RBS E)	NR	NR	Reported
Prenatal Immunization Status (PRS-E)			Not
Prenatal Immunization Status - Influenza	NR	NR NR	Reported
Prenatal Immunization Status - Tdap	NR NB	NR NR	Reported Not
Prenatal Immunization Status - Combination Prenatal Depression Screening and Follow-Up (PND-E)	NR	NR	Reported
Prenatal Depression Screening and Follow-Up - Depression	NR	NR	Not
Screening Prenatal Depression Screening and Follow-Up - Follow-Up on	NR	NR	Not Paparted
Positive Screen Postpartum Depression Screening and Follow-Up (PDS-E)			Reported
Postpartum Depression Screening and Follow-Up (FDS-E) Postpartum Depression Screening and Follow-Up - Depression Screening	NR	NR	Not Reported
Postpartum Depression Screening and Follow-Up - Follow-Up on	NR	NR	Not
Positive Screen		<u> </u>	Reported